Literature DB >> 12070296

Exploiting dendritic cells to improve vaccine efficacy.

Ralph M Steinman1, Melissa Pope.   

Abstract

Mesh：

Substances：

Year:  2002        PMID： 12070296      PMCID： PMC151021          DOI： 10.1172/JCI15962

Source DB:  PubMed          Journal:  J Clin Invest        ISSN： 0021-9738            Impact factor:   14.808


× No keyword cloud information.
  33 in total

Review 1.  Strategies for designing and optimizing new generation vaccines.

Authors:  J A Berzofsky; J D Ahlers; I M Belyakov
Journal:  Nat Rev Immunol       Date:  2001-12       Impact factor: 53.106

Review 2.  Toll-like receptors and innate immunity.

Authors:  R Medzhitov
Journal:  Nat Rev Immunol       Date:  2001-11       Impact factor: 53.106

Review 3.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

Review 4.  Dendritic cells and the control of immunity.

Authors:  J Banchereau; R M Steinman
Journal:  Nature       Date:  1998-03-19       Impact factor: 49.962

Review 5.  Mechanisms of MHC class I--restricted antigen processing.

Authors:  E Pamer; P Cresswell
Journal:  Annu Rev Immunol       Date:  1998       Impact factor: 28.527

Review 6.  Advances in vaccine adjuvants.

Authors:  M Singh; D O'Hagan
Journal:  Nat Biotechnol       Date:  1999-11       Impact factor: 54.908

Review 7.  The CD1 system: antigen-presenting molecules for T cell recognition of lipids and glycolipids.

Authors:  S A Porcelli; R L Modlin
Journal:  Annu Rev Immunol       Date:  1999       Impact factor: 28.527

8.  Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen.

Authors:  L J Sigal; S Crotty; R Andino; K L Rock
Journal:  Nature       Date:  1999-03-04       Impact factor: 49.962

Review 9.  Dendritic cell dynamics in the liver and hepatic lymph.

Authors:  K Matsuno; T Ezaki
Journal:  Int Rev Cytol       Date:  2000

Review 10.  Mobilizing dendritic cells for tolerance, priming, and chronic inflammation.

Authors:  F Sallusto; A Lanzavecchia
Journal:  J Exp Med       Date:  1999-02-15       Impact factor: 14.307
View more
  85 in total

1.  Enhancement of gp120-specific immune responses by genetic vaccination with the human immunodeficiency virus type 1 envelope gene fused to the gene coding for soluble CTLA4.

Authors:  Bishnu P Nayak; Gangadhara Sailaja; Abdul M Jabbar
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

Review 2.  Cancer vaccines: progress reveals new complexities.

Authors:  Zhiya Yu; Nicholas P Restifo
Journal:  J Clin Invest       Date:  2002-08       Impact factor: 14.808

3.  New directions in vaccine research.

Authors:  Peter Palese; Adolfo García-Sastre
Journal:  J Clin Invest       Date:  2002-06       Impact factor: 14.808

4.  The role of dendritic cells in the pharynx.

Authors:  Ake Davidsson; Jan Olofsson
Journal:  Eur Arch Otorhinolaryngol       Date:  2003-01-08       Impact factor: 2.503

Review 5.  Cross-priming in health and disease.

Authors:  Christian Kurts; Bruce W S Robinson; Percy A Knolle
Journal:  Nat Rev Immunol       Date:  2010-06       Impact factor: 53.106

6.  Dendritic cells infected by recombinant rabies virus vaccine vector expressing HIV-1 Gag are immunogenic even in the presence of vector-specific immunity.

Authors:  Celestine N Wanjalla; Elizabeth J Faul; Emily A Gomme; Matthias J Schnell
Journal:  Vaccine       Date:  2010-08-20       Impact factor: 3.641

7.  Activation of NF-kappaB by the intracellular expression of NF-kappaB-inducing kinase acts as a powerful vaccine adjuvant.

Authors:  E Andreakos; R O Williams; J Wales; B M Foxwell; M Feldmann
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-13       Impact factor: 11.205

8.  Lentivirus-delivered stable gene silencing by RNAi in primary cells.

Authors:  Sheila A Stewart; Derek M Dykxhoorn; Deborah Palliser; Hana Mizuno; Evan Y Yu; Dong Sung An; David M Sabatini; Irvin S Y Chen; William C Hahn; Phillip A Sharp; Robert A Weinberg; Carl D Novina
Journal:  RNA       Date:  2003-04       Impact factor: 4.942

Review 9.  SA-4-1BBL as a novel adjuvant for the development of therapeutic cancer vaccines.

Authors:  Rajesh K Sharma; Esma S Yolcu; Haval Shirwan
Journal:  Expert Rev Vaccines       Date:  2014-03       Impact factor: 5.217

10.  Novel plant virus-based vaccine induces protective cytotoxic T-lymphocyte-mediated antiviral immunity through dendritic cell maturation.

Authors:  Patrick Lacasse; Jérôme Denis; Réjean Lapointe; Denis Leclerc; Alain Lamarre
Journal:  J Virol       Date:  2007-11-07       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.